SCOHIA PHARMA

Tokyo, Japan· Est. 2020

A Japanese bioventure developing innovative small molecule drugs for metabolic, cardiovascular, and renal diseases through a diversified pipeline and strategic collaborations.

scohia.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

A Japanese bioventure developing innovative small molecule drugs for metabolic, cardiovascular, and renal diseases through a diversified pipeline and strategic collaborations.

MetabolicCardiovascularRenalEndocrineRare Diseases

Technology Platform

Small molecule drug discovery focused on novel mechanisms of action for lifestyle-related diseases, with strategy emphasizing different MOAs at each development stage and backup compounds in preclinical projects.

Opportunities

Large addressable markets in obesity, diabetes, and metabolic diseases; potential for first-in-class therapies with novel mechanisms like SSTR5 antagonism; additional partnership opportunities for Value-Added Pipeline assets.

Risk Factors

Early-stage pipeline with only one program in clinical trials; intense competition in metabolic disease space from large pharma and biotech companies; reliance on partners for development and commercialization of key assets.

Competitive Landscape

Competes in crowded metabolic disease space but differentiates through novel mechanisms like SSTR5 antagonism for endocrine disorders and quadruple agonist approach for obesity; faces competition from Novo Nordisk, Eli Lilly, and other GLP-1 developers.

More companies in Japan →